CN108192928A - Prepare ROSA26 gene mutations and the method rich in unrighted acid animal - Google Patents
Prepare ROSA26 gene mutations and the method rich in unrighted acid animal Download PDFInfo
- Publication number
- CN108192928A CN108192928A CN201810038598.1A CN201810038598A CN108192928A CN 108192928 A CN108192928 A CN 108192928A CN 201810038598 A CN201810038598 A CN 201810038598A CN 108192928 A CN108192928 A CN 108192928A
- Authority
- CN
- China
- Prior art keywords
- cell
- rosa26
- sfat1
- cas9
- dna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 65
- 241001465754 Metazoa Species 0.000 title claims abstract description 25
- 239000002253 acid Substances 0.000 title claims abstract description 23
- 206010064571 Gene mutation Diseases 0.000 title claims abstract description 17
- 108091033409 CRISPR Proteins 0.000 claims abstract description 87
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 87
- 108020004414 DNA Proteins 0.000 claims abstract description 62
- 108091027544 Subgenomic mRNA Proteins 0.000 claims abstract description 45
- 238000010354 CRISPR gene editing Methods 0.000 claims abstract description 42
- 230000014509 gene expression Effects 0.000 claims abstract description 30
- 230000035772 mutation Effects 0.000 claims abstract description 10
- 230000008685 targeting Effects 0.000 claims abstract description 9
- 239000002773 nucleotide Substances 0.000 claims abstract description 6
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 6
- 210000004027 cell Anatomy 0.000 claims description 82
- 239000000969 carrier Substances 0.000 claims description 25
- 238000006062 fragmentation reaction Methods 0.000 claims description 14
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 13
- 239000013598 vector Substances 0.000 claims description 11
- 239000013604 expression vector Substances 0.000 claims description 7
- 230000002068 genetic effect Effects 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 4
- 238000011144 upstream manufacturing Methods 0.000 claims description 4
- 125000001931 aliphatic group Chemical group 0.000 claims description 3
- 230000008859 change Effects 0.000 claims description 3
- 210000004962 mammalian cell Anatomy 0.000 claims description 3
- 238000003975 animal breeding Methods 0.000 claims description 2
- 230000010354 integration Effects 0.000 abstract description 12
- 239000007788 liquid Substances 0.000 description 16
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 16
- 230000029087 digestion Effects 0.000 description 15
- 235000013601 eggs Nutrition 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 11
- 210000003754 fetus Anatomy 0.000 description 11
- 210000002950 fibroblast Anatomy 0.000 description 11
- 238000013467 fragmentation Methods 0.000 description 11
- 210000001161 mammalian embryo Anatomy 0.000 description 10
- 210000000130 stem cell Anatomy 0.000 description 10
- 229910052799 carbon Inorganic materials 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 9
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 8
- 238000005520 cutting process Methods 0.000 description 8
- 230000006801 homologous recombination Effects 0.000 description 8
- 238000002744 homologous recombination Methods 0.000 description 8
- 241000282887 Suidae Species 0.000 description 7
- 238000001890 transfection Methods 0.000 description 7
- 238000012546 transfer Methods 0.000 description 7
- 230000009261 transgenic effect Effects 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- 241001045988 Neogene Species 0.000 description 6
- 108700019146 Transgenes Proteins 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 102000002322 Egg Proteins Human genes 0.000 description 5
- 108010000912 Egg Proteins Proteins 0.000 description 5
- 239000012894 fetal calf serum Substances 0.000 description 5
- 230000004927 fusion Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 102000006734 Beta-Globulins Human genes 0.000 description 4
- 108010087504 Beta-Globulins Proteins 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 238000001994 activation Methods 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 238000012239 gene modification Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 210000004681 ovum Anatomy 0.000 description 4
- 210000004508 polar body Anatomy 0.000 description 4
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 4
- 230000035935 pregnancy Effects 0.000 description 4
- 238000012797 qualification Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 239000012096 transfection reagent Substances 0.000 description 4
- 108091028113 Trans-activating crRNA Proteins 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000009395 breeding Methods 0.000 description 3
- 239000006143 cell culture medium Substances 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 238000003209 gene knockout Methods 0.000 description 3
- 230000005017 genetic modification Effects 0.000 description 3
- 235000013617 genetically modified food Nutrition 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000001638 lipofection Methods 0.000 description 3
- 230000035800 maturation Effects 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 241000701161 unidentified adenovirus Species 0.000 description 3
- 239000013603 viral vector Substances 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- CTWCFPWFIGRAEP-CIUDSAMLSA-N Asp-Lys-Asp Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(O)=O CTWCFPWFIGRAEP-CIUDSAMLSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000244201 Caenorhabditis briggsae Species 0.000 description 2
- 101100012567 Caenorhabditis elegans fat-1 gene Proteins 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 239000007836 KH2PO4 Substances 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241000244206 Nematoda Species 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 2
- 108010052090 Renilla Luciferases Proteins 0.000 description 2
- 235000011449 Rosa Nutrition 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 238000010459 TALEN Methods 0.000 description 2
- 108010017070 Zinc Finger Nucleases Proteins 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 150000001336 alkenes Chemical class 0.000 description 2
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 238000005138 cryopreservation Methods 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012154 double-distilled water Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000010362 genome editing Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 108010055341 glutamyl-glutamic acid Proteins 0.000 description 2
- 101150044508 key gene Proteins 0.000 description 2
- 108010030617 leucyl-phenylalanyl-valine Proteins 0.000 description 2
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 101150091879 neo gene Proteins 0.000 description 2
- 235000020665 omega-6 fatty acid Nutrition 0.000 description 2
- 210000000287 oocyte Anatomy 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 101150112497 26 gene Proteins 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- WDIYWDJLXOCGRW-ACZMJKKPSA-N Ala-Asp-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O WDIYWDJLXOCGRW-ACZMJKKPSA-N 0.000 description 1
- 108010076441 Ala-His-His Proteins 0.000 description 1
- OKIKVSXTXVVFDV-MMWGEVLESA-N Ala-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](C)N OKIKVSXTXVVFDV-MMWGEVLESA-N 0.000 description 1
- VHVVPYOJIIQCKS-QEJZJMRPSA-N Ala-Leu-Phe Chemical compound C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 VHVVPYOJIIQCKS-QEJZJMRPSA-N 0.000 description 1
- PEIBBAXIKUAYGN-UBHSHLNASA-N Ala-Phe-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)C)CC1=CC=CC=C1 PEIBBAXIKUAYGN-UBHSHLNASA-N 0.000 description 1
- YCRAFFCYWOUEOF-DLOVCJGASA-N Ala-Phe-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)C)CC1=CC=CC=C1 YCRAFFCYWOUEOF-DLOVCJGASA-N 0.000 description 1
- CYBJZLQSUJEMAS-LFSVMHDDSA-N Ala-Phe-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](C)N)O CYBJZLQSUJEMAS-LFSVMHDDSA-N 0.000 description 1
- YHBDGLZYNIARKJ-GUBZILKMSA-N Ala-Pro-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)N YHBDGLZYNIARKJ-GUBZILKMSA-N 0.000 description 1
- HKRXJBBCQBAGIM-FXQIFTODSA-N Arg-Asp-Ser Chemical compound C(C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)O)N)CN=C(N)N HKRXJBBCQBAGIM-FXQIFTODSA-N 0.000 description 1
- KMFPQTITXUKJOV-DCAQKATOSA-N Arg-Ser-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O KMFPQTITXUKJOV-DCAQKATOSA-N 0.000 description 1
- CGWVCWFQGXOUSJ-ULQDDVLXSA-N Arg-Tyr-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(O)=O CGWVCWFQGXOUSJ-ULQDDVLXSA-N 0.000 description 1
- YGHCVNQOZZMHRZ-DJFWLOJKSA-N Asn-His-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](CC(=O)N)N YGHCVNQOZZMHRZ-DJFWLOJKSA-N 0.000 description 1
- ACKNRKFVYUVWAC-ZPFDUUQYSA-N Asn-Ile-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)N)N ACKNRKFVYUVWAC-ZPFDUUQYSA-N 0.000 description 1
- ATYWBXGNXZYZGI-ACZMJKKPSA-N Asp-Asn-Gln Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O ATYWBXGNXZYZGI-ACZMJKKPSA-N 0.000 description 1
- XDGBFDYXZCMYEX-NUMRIWBASA-N Asp-Glu-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)N)O XDGBFDYXZCMYEX-NUMRIWBASA-N 0.000 description 1
- QCVXMEHGFUMKCO-YUMQZZPRSA-N Asp-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC(O)=O QCVXMEHGFUMKCO-YUMQZZPRSA-N 0.000 description 1
- SNDBKTFJWVEVPO-WHFBIAKZSA-N Asp-Gly-Ser Chemical compound [H]N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(O)=O SNDBKTFJWVEVPO-WHFBIAKZSA-N 0.000 description 1
- NHSDEZURHWEZPN-SXTJYALSSA-N Asp-Ile-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)NC(=O)[C@H](CC(=O)O)N NHSDEZURHWEZPN-SXTJYALSSA-N 0.000 description 1
- ORRJQLIATJDMQM-HJGDQZAQSA-N Asp-Leu-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(O)=O ORRJQLIATJDMQM-HJGDQZAQSA-N 0.000 description 1
- 238000010356 CRISPR-Cas9 genome editing Methods 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- HNNGTYHNYDOSKV-FXQIFTODSA-N Cys-Cys-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CS)N HNNGTYHNYDOSKV-FXQIFTODSA-N 0.000 description 1
- HSAWNMMTZCLTPY-DCAQKATOSA-N Cys-Met-Leu Chemical compound SC[C@H](N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(O)=O HSAWNMMTZCLTPY-DCAQKATOSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 101000933126 Escherichia coli (strain K12) CRISPR system Cascade subunit CasE Proteins 0.000 description 1
- 101000933127 Escherichia coli (strain UTI89 / UPEC) CRISPR-associated endonuclease Cas6/Csy4 Proteins 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- ZDJZEGYVKANKED-NRPADANISA-N Gln-Cys-Val Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(O)=O ZDJZEGYVKANKED-NRPADANISA-N 0.000 description 1
- ZBKUIQNCRIYVGH-SDDRHHMPSA-N Gln-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCC(=O)N)N ZBKUIQNCRIYVGH-SDDRHHMPSA-N 0.000 description 1
- YRHZWVKUFWCEPW-GLLZPBPUSA-N Gln-Thr-Gln Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CCC(=O)N)N)O YRHZWVKUFWCEPW-GLLZPBPUSA-N 0.000 description 1
- SGVGIVDZLSHSEN-RYUDHWBXSA-N Gln-Tyr-Gly Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)NCC(O)=O SGVGIVDZLSHSEN-RYUDHWBXSA-N 0.000 description 1
- ICRKQMRFXYDYMK-LAEOZQHASA-N Gln-Val-Asn Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O ICRKQMRFXYDYMK-LAEOZQHASA-N 0.000 description 1
- FYBSCGZLICNOBA-XQXXSGGOSA-N Glu-Ala-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O FYBSCGZLICNOBA-XQXXSGGOSA-N 0.000 description 1
- DYFJZDDQPNIPAB-NHCYSSNCSA-N Glu-Arg-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(O)=O DYFJZDDQPNIPAB-NHCYSSNCSA-N 0.000 description 1
- ILGFBUGLBSAQQB-GUBZILKMSA-N Glu-Glu-Arg Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O ILGFBUGLBSAQQB-GUBZILKMSA-N 0.000 description 1
- HILMIYALTUQTRC-XVKPBYJWSA-N Glu-Gly-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O HILMIYALTUQTRC-XVKPBYJWSA-N 0.000 description 1
- OQXDUSZKISQQSS-GUBZILKMSA-N Glu-Lys-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O OQXDUSZKISQQSS-GUBZILKMSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- HHSOPSCKAZKQHQ-PEXQALLHSA-N Gly-His-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)CN HHSOPSCKAZKQHQ-PEXQALLHSA-N 0.000 description 1
- QVDGHDFFYHKJPN-QWRGUYRKSA-N Gly-Phe-Cys Chemical compound NCC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CS)C(O)=O QVDGHDFFYHKJPN-QWRGUYRKSA-N 0.000 description 1
- 108020005004 Guide RNA Proteins 0.000 description 1
- QQQHYJFKDLDUNK-CIUDSAMLSA-N His-Asp-Cys Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CS)C(=O)O)N QQQHYJFKDLDUNK-CIUDSAMLSA-N 0.000 description 1
- VTMLJMNQHKBPON-QWRGUYRKSA-N His-Gly-His Chemical compound C([C@H](N)C(=O)NCC(=O)N[C@@H](CC=1NC=NC=1)C(O)=O)C1=CN=CN1 VTMLJMNQHKBPON-QWRGUYRKSA-N 0.000 description 1
- OZBDSFBWIDPVDA-BZSNNMDCSA-N His-His-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](CC3=CN=CN3)N OZBDSFBWIDPVDA-BZSNNMDCSA-N 0.000 description 1
- ZUELLZFHJUPFEC-PMVMPFDFSA-N His-Phe-Trp Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)C1=CN=CN1 ZUELLZFHJUPFEC-PMVMPFDFSA-N 0.000 description 1
- VIJMRAIWYWRXSR-CIUDSAMLSA-N His-Ser-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CN=CN1 VIJMRAIWYWRXSR-CIUDSAMLSA-N 0.000 description 1
- KFQDSSNYWKZFOO-LSJOCFKGSA-N His-Val-Ala Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(O)=O KFQDSSNYWKZFOO-LSJOCFKGSA-N 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- YGDWPQCLFJNMOL-MNXVOIDGSA-N Ile-Leu-Gln Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N YGDWPQCLFJNMOL-MNXVOIDGSA-N 0.000 description 1
- BJECXJHLUJXPJQ-PYJNHQTQSA-N Ile-Pro-His Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)N BJECXJHLUJXPJQ-PYJNHQTQSA-N 0.000 description 1
- YKZAMJXNJUWFIK-JBDRJPRFSA-N Ile-Ser-Ala Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)O)N YKZAMJXNJUWFIK-JBDRJPRFSA-N 0.000 description 1
- YCKPUHHMCFSUMD-IUKAMOBKSA-N Ile-Thr-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)O)C(=O)O)N YCKPUHHMCFSUMD-IUKAMOBKSA-N 0.000 description 1
- 150000008540 L-glutamines Chemical class 0.000 description 1
- RCFDOSNHHZGBOY-UHFFFAOYSA-N L-isoleucyl-L-alanine Natural products CCC(C)C(N)C(=O)NC(C)C(O)=O RCFDOSNHHZGBOY-UHFFFAOYSA-N 0.000 description 1
- 241001071864 Lethrinus laticaudis Species 0.000 description 1
- PVMPDMIKUVNOBD-CIUDSAMLSA-N Leu-Asp-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O PVMPDMIKUVNOBD-CIUDSAMLSA-N 0.000 description 1
- QLQHWWCSCLZUMA-KKUMJFAQSA-N Leu-Asp-Tyr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 QLQHWWCSCLZUMA-KKUMJFAQSA-N 0.000 description 1
- OGUUKPXUTHOIAV-SDDRHHMPSA-N Leu-Glu-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N1CCC[C@@H]1C(=O)O)N OGUUKPXUTHOIAV-SDDRHHMPSA-N 0.000 description 1
- CFZZDVMBRYFFNU-QWRGUYRKSA-N Leu-His-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)NCC(O)=O CFZZDVMBRYFFNU-QWRGUYRKSA-N 0.000 description 1
- FIICHHJDINDXKG-IHPCNDPISA-N Leu-Lys-Trp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O FIICHHJDINDXKG-IHPCNDPISA-N 0.000 description 1
- BIZNDKMFQHDOIE-KKUMJFAQSA-N Leu-Phe-Asn Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(O)=O)CC1=CC=CC=C1 BIZNDKMFQHDOIE-KKUMJFAQSA-N 0.000 description 1
- AIRUUHAOKGVJAD-JYJNAYRXSA-N Leu-Phe-Glu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O AIRUUHAOKGVJAD-JYJNAYRXSA-N 0.000 description 1
- PTRKPHUGYULXPU-KKUMJFAQSA-N Leu-Phe-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(O)=O PTRKPHUGYULXPU-KKUMJFAQSA-N 0.000 description 1
- LFXSPAIBSZSTEM-PMVMPFDFSA-N Leu-Trp-Phe Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)O)N LFXSPAIBSZSTEM-PMVMPFDFSA-N 0.000 description 1
- LMDVGHQPPPLYAR-IHRRRGAJSA-N Leu-Val-His Chemical compound N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)O LMDVGHQPPPLYAR-IHRRRGAJSA-N 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- WSXTWLJHTLRFLW-SRVKXCTJSA-N Lys-Ala-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(O)=O WSXTWLJHTLRFLW-SRVKXCTJSA-N 0.000 description 1
- QKXZCUCBFPEXNK-KKUMJFAQSA-N Lys-Leu-His Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 QKXZCUCBFPEXNK-KKUMJFAQSA-N 0.000 description 1
- QQPSCXKFDSORFT-IHRRRGAJSA-N Lys-Lys-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCCN QQPSCXKFDSORFT-IHRRRGAJSA-N 0.000 description 1
- LKDXINHHSWFFJC-SRVKXCTJSA-N Lys-Ser-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)N LKDXINHHSWFFJC-SRVKXCTJSA-N 0.000 description 1
- YKBSXQFZWFXFIB-VOAKCMCISA-N Lys-Thr-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CCCCN)C(O)=O YKBSXQFZWFXFIB-VOAKCMCISA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- RXWPLVRJQNWXRQ-IHRRRGAJSA-N Met-His-His Chemical compound C([C@H](NC(=O)[C@@H](N)CCSC)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)C1=CNC=N1 RXWPLVRJQNWXRQ-IHRRRGAJSA-N 0.000 description 1
- MQASRXPTQJJNFM-JYJNAYRXSA-N Met-Pro-Phe Chemical compound CSCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MQASRXPTQJJNFM-JYJNAYRXSA-N 0.000 description 1
- LUYURUYVNYGKGM-RCWTZXSCSA-N Met-Pro-Thr Chemical compound CSCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(O)=O LUYURUYVNYGKGM-RCWTZXSCSA-N 0.000 description 1
- YGNUDKAPJARTEM-GUBZILKMSA-N Met-Val-Ala Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(O)=O YGNUDKAPJARTEM-GUBZILKMSA-N 0.000 description 1
- 229910017621 MgSO4-7H2O Inorganic materials 0.000 description 1
- 241000907999 Mortierella alpina Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- AUEJLPRZGVVDNU-UHFFFAOYSA-N N-L-tyrosyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CC1=CC=C(O)C=C1 AUEJLPRZGVVDNU-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 101000933153 Pectobacterium atrosepticum (strain SCRI 1043 / ATCC BAA-672) CRISPR-associated endonuclease Cas6f/Csy4 Proteins 0.000 description 1
- ZWJKVFAYPLPCQB-UNQGMJICSA-N Phe-Arg-Thr Chemical compound C[C@@H](O)[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)Cc1ccccc1)C(O)=O ZWJKVFAYPLPCQB-UNQGMJICSA-N 0.000 description 1
- KAHUBGWSIQNZQQ-KKUMJFAQSA-N Phe-Asn-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 KAHUBGWSIQNZQQ-KKUMJFAQSA-N 0.000 description 1
- HOYQLNNGMHXZDW-KKUMJFAQSA-N Phe-Glu-Arg Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O HOYQLNNGMHXZDW-KKUMJFAQSA-N 0.000 description 1
- APJPXSFJBMMOLW-KBPBESRZSA-N Phe-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC1=CC=CC=C1 APJPXSFJBMMOLW-KBPBESRZSA-N 0.000 description 1
- IWZRODDWOSIXPZ-IRXDYDNUSA-N Phe-Phe-Gly Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(O)=O)C1=CC=CC=C1 IWZRODDWOSIXPZ-IRXDYDNUSA-N 0.000 description 1
- ZLAKUZDMKVKFAI-JYJNAYRXSA-N Phe-Pro-Val Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(O)=O ZLAKUZDMKVKFAI-JYJNAYRXSA-N 0.000 description 1
- APECKGGXAXNFLL-RNXOBYDBSA-N Phe-Trp-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=CC=C1 APECKGGXAXNFLL-RNXOBYDBSA-N 0.000 description 1
- GCFNFKNPCMBHNT-IRXDYDNUSA-N Phe-Tyr-Gly Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)NCC(=O)O)N GCFNFKNPCMBHNT-IRXDYDNUSA-N 0.000 description 1
- GLUYKHMBGKQBHE-JYJNAYRXSA-N Phe-Val-Arg Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CC1=CC=CC=C1 GLUYKHMBGKQBHE-JYJNAYRXSA-N 0.000 description 1
- 241000255969 Pieris brassicae Species 0.000 description 1
- CYQQWUPHIZVCNY-GUBZILKMSA-N Pro-Arg-Ser Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(O)=O CYQQWUPHIZVCNY-GUBZILKMSA-N 0.000 description 1
- DTQIXTOJHKVEOH-DCAQKATOSA-N Pro-His-Cys Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CC2=CN=CN2)C(=O)N[C@@H](CS)C(=O)O DTQIXTOJHKVEOH-DCAQKATOSA-N 0.000 description 1
- FKYKZHOKDOPHSA-DCAQKATOSA-N Pro-Leu-Ser Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O FKYKZHOKDOPHSA-DCAQKATOSA-N 0.000 description 1
- GNFHQWNCSSPOBT-ULQDDVLXSA-N Pro-Trp-Gln Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)N[C@@H](CCC(=O)N)C(=O)O GNFHQWNCSSPOBT-ULQDDVLXSA-N 0.000 description 1
- DYJTXTCEXMCPBF-UFYCRDLUSA-N Pro-Tyr-Phe Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)O DYJTXTCEXMCPBF-UFYCRDLUSA-N 0.000 description 1
- VEUACYMXJKXALX-IHRRRGAJSA-N Pro-Tyr-Ser Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(O)=O VEUACYMXJKXALX-IHRRRGAJSA-N 0.000 description 1
- 238000012181 QIAquick gel extraction kit Methods 0.000 description 1
- 241000242739 Renilla Species 0.000 description 1
- 241000172147 Saprolegnia diclina Species 0.000 description 1
- JPIDMRXXNMIVKY-VZFHVOOUSA-N Ser-Ala-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O JPIDMRXXNMIVKY-VZFHVOOUSA-N 0.000 description 1
- CXBFHZLODKPIJY-AAEUAGOBSA-N Ser-Gly-Trp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CO)N CXBFHZLODKPIJY-AAEUAGOBSA-N 0.000 description 1
- VZQRNAYURWAEFE-KKUMJFAQSA-N Ser-Leu-Phe Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 VZQRNAYURWAEFE-KKUMJFAQSA-N 0.000 description 1
- MQUZANJDFOQOBX-SRVKXCTJSA-N Ser-Phe-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(O)=O MQUZANJDFOQOBX-SRVKXCTJSA-N 0.000 description 1
- KKKVOZNCLALMPV-XKBZYTNZSA-N Ser-Thr-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(O)=O KKKVOZNCLALMPV-XKBZYTNZSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- ZQUKYJOKQBRBCS-GLLZPBPUSA-N Thr-Gln-Gln Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N)O ZQUKYJOKQBRBCS-GLLZPBPUSA-N 0.000 description 1
- CRZNCABIJLRFKZ-IUKAMOBKSA-N Thr-Ile-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H]([C@@H](C)O)N CRZNCABIJLRFKZ-IUKAMOBKSA-N 0.000 description 1
- VTVVYQOXJCZVEB-WDCWCFNPSA-N Thr-Leu-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O VTVVYQOXJCZVEB-WDCWCFNPSA-N 0.000 description 1
- FYBFTPLPAXZBOY-KKHAAJSZSA-N Thr-Val-Asp Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O FYBFTPLPAXZBOY-KKHAAJSZSA-N 0.000 description 1
- UUIYFDAWNBSWPG-IHPCNDPISA-N Trp-Lys-Lys Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)O)N UUIYFDAWNBSWPG-IHPCNDPISA-N 0.000 description 1
- GBEAUNVBIMLWIB-IHPCNDPISA-N Trp-Ser-Phe Chemical compound C([C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)N)C(O)=O)C1=CC=CC=C1 GBEAUNVBIMLWIB-IHPCNDPISA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- WPVGRKLNHJJCEN-BZSNNMDCSA-N Tyr-Asp-Phe Chemical compound C([C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=C(O)C=C1 WPVGRKLNHJJCEN-BZSNNMDCSA-N 0.000 description 1
- SLCSPPCQWUHPPO-JYJNAYRXSA-N Tyr-Glu-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 SLCSPPCQWUHPPO-JYJNAYRXSA-N 0.000 description 1
- FBHBVXUBTYVCRU-BZSNNMDCSA-N Tyr-His-Leu Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CN=CN1 FBHBVXUBTYVCRU-BZSNNMDCSA-N 0.000 description 1
- CNNVVEPJTFOGHI-ACRUOGEOSA-N Tyr-Lys-Tyr Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O CNNVVEPJTFOGHI-ACRUOGEOSA-N 0.000 description 1
- PWKMJDQXKCENMF-MEYUZBJRSA-N Tyr-Thr-Leu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O PWKMJDQXKCENMF-MEYUZBJRSA-N 0.000 description 1
- JRMCISZDVLOTLR-BVSLBCMMSA-N Tyr-Trp-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CC3=CC=C(C=C3)O)N JRMCISZDVLOTLR-BVSLBCMMSA-N 0.000 description 1
- COYSIHFOCOMGCF-WPRPVWTQSA-N Val-Arg-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CCCN=C(N)N COYSIHFOCOMGCF-WPRPVWTQSA-N 0.000 description 1
- COYSIHFOCOMGCF-UHFFFAOYSA-N Val-Arg-Gly Natural products CC(C)C(N)C(=O)NC(C(=O)NCC(O)=O)CCCN=C(N)N COYSIHFOCOMGCF-UHFFFAOYSA-N 0.000 description 1
- YCMXFKWYJFZFKS-LAEOZQHASA-N Val-Gln-Asp Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)O)N YCMXFKWYJFZFKS-LAEOZQHASA-N 0.000 description 1
- FEXILLGKGGTLRI-NHCYSSNCSA-N Val-Leu-Asn Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](C(C)C)N FEXILLGKGGTLRI-NHCYSSNCSA-N 0.000 description 1
- WFTKOJGOOUJLJV-VKOGCVSHSA-N Val-Trp-Ile Chemical compound C1=CC=C2C(C[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C([O-])=O)NC(=O)[C@@H]([NH3+])C(C)C)=CNC2=C1 WFTKOJGOOUJLJV-VKOGCVSHSA-N 0.000 description 1
- AEFJNECXZCODJM-UWVGGRQHSA-N Val-Val-Gly Chemical compound CC(C)[C@H]([NH3+])C(=O)N[C@@H](C(C)C)C(=O)NCC([O-])=O AEFJNECXZCODJM-UWVGGRQHSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 108010070944 alanylhistidine Proteins 0.000 description 1
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 108010077245 asparaginyl-proline Proteins 0.000 description 1
- 108010069205 aspartyl-phenylalanine Proteins 0.000 description 1
- 108010047857 aspartylglycine Proteins 0.000 description 1
- 108010068265 aspartyltyrosine Proteins 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 210000001771 cumulus cell Anatomy 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 108010054813 diprotin B Proteins 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 229910052564 epsomite Inorganic materials 0.000 description 1
- 230000012173 estrus Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000008217 follicular development Effects 0.000 description 1
- 231100000221 frame shift mutation induction Toxicity 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000012215 gene cloning Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 108010077435 glycyl-phenylalanyl-glycine Proteins 0.000 description 1
- 108010059898 glycyl-tyrosyl-lysine Proteins 0.000 description 1
- 108010010147 glycylglutamine Proteins 0.000 description 1
- 108010020688 glycylhistidine Proteins 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
- 108010028295 histidylhistidine Proteins 0.000 description 1
- 102000057593 human F8 Human genes 0.000 description 1
- VVIUBCNYACGLLV-UHFFFAOYSA-N hypotaurine Chemical compound [NH3+]CCS([O-])=O VVIUBCNYACGLLV-UHFFFAOYSA-N 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000012966 insertion method Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 108010031424 isoleucyl-prolyl-proline Proteins 0.000 description 1
- 238000002350 laparotomy Methods 0.000 description 1
- 108010064235 lysylglycine Proteins 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000002894 multi-fate stem cell Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 210000002394 ovarian follicle Anatomy 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 108010082795 phenylalanyl-arginyl-arginine Proteins 0.000 description 1
- 108010084525 phenylalanyl-phenylalanyl-glycine Proteins 0.000 description 1
- 108010073025 phenylalanylphenylalanine Proteins 0.000 description 1
- 108010051242 phenylalanylserine Proteins 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108010090894 prolylleucine Proteins 0.000 description 1
- 238000012113 quantitative test Methods 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 229940047431 recombinate Drugs 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000012857 repacking Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 108010048818 seryl-histidine Proteins 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000033772 system development Effects 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 108010003137 tyrosyltyrosine Proteins 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/108—Swine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/02—Animal zootechnically ameliorated
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Environmental Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Animal Husbandry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Biodiversity & Conservation Biology (AREA)
- Cell Biology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention discloses ROSA26 gene mutations are prepared and the method rich in unrighted acid animal.The method of mutation ROSA26 genes disclosed by the invention is carried out using CRISPR/Cas9 systems, and CRISPR/Cas9 systems include the sgRNA of targeting ROSA26 genes, and the target sequence of sgRNA is the nucleotide sequence of sequence 2 in sequence table;Donor dna of this method by importing sgRNA and Cas9 into recipient cell and containing Sfat1 expression casettes realizes the mutation of ROSA26 genes.It is demonstrated experimentally that the method using the present invention can be with successful knockout ROSA26 genes, and site-directed integration Sfat1 genes finally successfully obtain the animal of expression Sfat1.
Description
Technical field
The present invention relates to ROSA26 gene mutations in biotechnology, are prepared and the side rich in unrighted acid animal
Method.
Background technology
Polyunsaturated fatty acid (PUFAs) is a kind of aliphatic acid for being widely studied and paying close attention to.PUFAs mainly includes ω -6
With ω -3PUFAs two types, each type all includes multiple from short carbon chain (18C) to Long carbon chain (22C) and contains more
The aliphatic acid of a unsaturated bond.More and more researchs have shown that PUFAs has extensive biological function, they participate in cell
The composition of film and as the signaling molecule during many cell responses, is closely related with a variety of diseases of the mankind,
Suitable content is of crucial importance for the normal development of the mankind and other mammals and holding good condition of health.ω-
6PUFAs on the whole for have little significance to human body, excessive intake is detrimental to health instead.ω -3PUFAs by
Confirm the important role in terms of a variety of diseases such as prevention and treatment angiocardiopathy, arthritis, cancer.Wherein it is particularly 22
The EPA of the DHA of six alkene of carbon and 20 light dydrocarbon alkene have important positive effect to health.
The hot spot and direction that ω -3PUFAs are current high-quality pig breedings are produced in pork by transgenic technology.
Omega-3-aliphatic acid desaturase gene be ω -3PUFAs synthesis key gene, they using ω -6PUFAs for substrate in fat
Sour carbochain methyl end third carbon catalysis generates a unsaturated bond (ethylene linkage) and synthesizes corresponding ω -3PUFAs.In recent years, respectively
The scientist of state has cloned multiple omega-3-aliphatic acid desaturase genes, but wherein most gene can only synthesize the ω of 18 carbon-
3PUFAs, value of exploiting and utilizing are little.Although ω -3PUFAs the genes of more long-chain, such as fungi can be synthesized by also having been reported that
The omega-3-aliphatic acid desaturase of Saprolegnia diclina can synthesize the ω -3PUFAs of 20 carbon, another fungi
The 1S-4 of Mortierella alpina is not only able to the ω -3PUFAs of 20 carbon of synthesis, moreover it is possible to synthesize the ω -3PUFAs of 18 carbon.
The gene for being really used for such research comes from the omega-3-aliphatic acid desaturase gene (Fat1) of nematode C.elegans.
The gene is transferred into the content increase that can make in mammalian cell and mouse from the ω -3PUFAs of 18 carbon to 22 carbon, display
It is out very big can value of exploiting and utilizing.Come from the omega-3-aliphatic acid desaturase gene Sfat1 of nematode C.briggasae
(similar to Fat1), can get through the approach that ω -6 is converted to omega-3 polyunsaturated fatty acids, the random integration of preparation
Sfat1 transgene clone pigs, the content of omega-fatty acid are improved largely, 20 carbon in Sfat1 transgene pig musculatures
EPA accounts for about the 16% of total fatty acid content, and the DHA of 22 carbon accounts for about the 4% of total fatty acid content.It is transferred to gene constructed turn of Sfat1
Gene cloning pig is to prepare the effective means rich in omega-3 polyunsaturated fatty acids transgene pig.
Pig embryos stem cell, which is not yet successfully built, so far is, the pig induction prepared using induced multi-potent stem cell technology is more
Energy stem cell is fitted into ability without system genitale, prepares genetic modification pig and depends on somatic cell gene modification and body cell
Nuclear transfer technology.At present, the genetic modification of body cell mainly has two kinds of host gene site-directed integration and foreign gene radom insertion
Method.Target gene is integrated into host genome using conventional carrier, transposon vector or viral vectors, integration process
Belong to random process, target gene is incorporated into position in host genome and copy number is uncontrollable.It is main using random transgenosis
It has the following problems:(1) exogenous origin gene integrator host genome position is uncontrollable, it is possible to host gene be damaged, especially
It is using when transposon vector and viral vectors its be more biased towards in being integrated into host transcription active region;(2) foreign gene is in place
Copy number in key-gene group is not known, and the genetically modified animal obtained genotype in succeeding generations is inconsistent;(3) external source
The random integration of gene causes its differential expression and individual phenotype between each tissue of host and individual to differ;(4) external source
The radom insertion of gene is easily methylated especially with its foreign gene promoter during viral vectors, causes foreign gene
Silence.These shortcomings seriously constrain the cultivation and application of genetic modification pig.
CRISPR/Cas9 originates from a kind of efficient bacterial immune defense mechanism, is many bacteriums and most of Archimycetes
Natural immune system, the identification of specificity is carried out by the virus to invasion and nucleic acid, is cut using Cas9 albumen, from
And reach the protection to itself.CRISPR/Cas9 gene editing technologies based on this system development, can be conveniently and efficiently real
Now the fixed point of genome is sheared, realizes the quick editor to target gene.Caused by efficiently solving conventional transgenic modification
Problems provide effective approach to prepare the model that exogenous gene expression is stable, phenotype is consistent, gene are pushed to repair significantly
Adorn the research and application of big animal model.During gene site-directed modification, need for some foreign genes, such as exogenous merit base
Because provide one it is safe and reliable berth at " harbour ", these " harbour " foreign genes not only can stability and high efficiency expression, but also to cell
With tissue without known side effect.Transgenic mice research shows that:ROSA26 gene locis are in each period of development, almost
All cells can efficient mediate foreign gene expression, and the vigor of the depletion on cell of ROSA26 genes and function are not
It has an impact.
CRISPR/Cas9 systems are that a kind of defense mechanism of exotic invasive microorganism is resisted in bacterium and archeobacteria, afterwards quilt
Gene editing system is transformed into, with TALEN (transcription activator-like effector nuclease)
And ZFN (zinc-finger nuclease) technology becomes three big genome edit tools side by side.CRISPR-Cas9 systems by
Three parts element form, Cas9 endonucleases, crRNA and tracrRNA, crRNA can specific recognition section of DNA sequence,
TracrRNA plays a part of to connect crRNA and Cas9 endonucleases, and Cas9 endonucleases draw crRNA-tracrRNA's
Lower adjustable point cutting DNA is led, DNA double chain is caused to be broken, cell starts self-regeneration mechanism, is carried out by non-end with linking sources
It repairs, and generates frameshift mutation (be inserted into or missing) and cause the forfeiture of gene function, realize the purpose of gene knockout.
CrRNA and tracrRNA can also be by " repackings " into a guide RNA (single-guide RNA, sgRNA), this sgRNA
It is enough Cas9 endonucleases is helped to carry out DNA fixed point cutting, realizes gene knockout.
Invention content
The object of the present invention is to provide the methods for being rich in unrighted acid animal for being mutated ROSA26 genes with preparation.
Present invention firstly provides the method for mutation ROSA26 genes, the method is carried out using CRISPR/Cas9 systems,
The CRISPR/Cas9 systems include the sgRNA of targeting ROSA26 genes, and the target sequence of the sgRNA is following A1), A2) or
A3):
A1) in sequence table sequence 2 nucleotide sequence;
A2 the DNA sequence dna) and A1) limited have 75% or more than 75% homogeneity as A1) derived from DNA sequence dna;
A3) under strict conditions with A1) limit DNA sequence dna hybridize as A1) derived from DNA sequence dna.
The method may also include and the sgRNA and Cas9 is imported into recipient cell, realize the mutation of ROSA26 genes.
In the above method, the sgRNA and the Cas9 of being imported into recipient cell will be by that will contain the volume of the sgRNA
The expression vector of the expression vector of code gene and the encoding gene containing Cas9, which is imported in the recipient cell, to be realized.
In the above method, the expression vector of the encoding gene containing the sgRNA and the coding containing Cas9
The expression vector of gene can be same carrier, which is named as carrier 1, the carrier 1 be by BsmB I to
The recombinant vector that DNA fragmentation in CRISPR/Cas9 carriers shown in insetion sequence 2 obtains, the carrier 1 can express claim
SgRNA and Cas9 described in 1.
The method may also include and donor dna is imported into the recipient cell, realize the mutation of ROSA26 genes, described
Donor dna contains two DNA fragmentations for being located at the target sequence upstream and downstream in ROSA26 genes.
In the above method, expression cassette of the donor dna also containing Sfat1 encoding genes or Sfat1 encoding genes.
The sequence of the Sfat1 can be the protein shown in sequence table SEQ ID NO.10.
The Sfat1 encoding genes concretely DNA in sequence table shown in 2744-3943 of SEQ ID NO.9
Molecule.
The expression cassette is concretely 1400-4442 of SEQ ID NO.9 in sequence table.
The donor dna can also contain neo genes.In one embodiment of the invention, the donor dna is sequence table
DNA fragmentation shown in middle SEQ ID NO.9, wherein, the 1-8 identification sequences for Not I of SEQ ID NO.9,9-998
Position for left homology arm sequence, 998-1003 be Hpa I identification sequence, the 1400-2641 sequences for CAG promoters
Row, the 2744-3943 gene orders for Sfat1, the 4030-4442 sequences for rabbit β-globulin polyA, the
The 4504-4538 sequences for loxP, 4564-5070 are PGK promoter sequences, and 5081-5884 are neo gene sequences
Row, 6375-6408 be loxP sequence, 6414-6419 for Sal I identify sequence, 6420-7970 be the right side together
Source arm sequence, 7987-7970 are the identification sequence of Not I.
Any one of the present invention also provides following 1) -6):
1) method for preparing ROSA26 Genetic Mutant Cells, including:ROSA26 genes are prepared using the method to dash forward
The cell of change;
2) method for preparing ROSA26 gene mutant animals, including:ROSA26 gene mutations are prepared using the method
Zooblast prepares ROSA26 gene mutant animals using the zooblast of the ROSA26 gene mutations;
3) method for preparing expression Sfat1 cells, including:The animal that ROSA26 gene mutations are prepared using the method is thin
Born of the same parents obtain the cell of expression Sfat1;
4) method for preparing expression Sfat1 animals, including:The animal that ROSA26 gene mutations are prepared using the method is thin
Born of the same parents obtain the cell of expression Sfat1;The animal of expression Sfat1 is prepared using the cell of the expression Sfat1;
5) method rich in unrighted acid cell is prepared, including:ROSA26 gene mutations are prepared using the method
Zooblast, obtain the cell rich in unrighted acid;
6) method rich in unrighted acid animal is prepared, including:ROSA26 gene mutations are prepared using the method
Zooblast, obtain expression Sfat1 cell;It is prepared using the cell of the expression Sfat1 rich in unrighted acid
Animal.
In the above method, the cell can be following a1) or a2) or a3):
A1) zooblast;
A2) mammalian cell;
A3) pig cell;
The animal can be b1) or b2):
B1) mammal;
A2) pig.
The present invention also provides application of the method in animal breeding.
In above application, the animal can be b1) or b2):
B1) mammal;
A2) pig.
In the present invention, the pig cell can be pig fibroblast, such as porcine fetus fibroblasts.
It is demonstrated experimentally that the method using the present invention can be with successful knockout ROSA26 genes, and site-directed integration Sfat1 genes,
The final animal for successfully obtaining expression Sfat1.The present invention organically combines transgenic breeding technology and traditional breeding method, is to add
The important means and effective way of the high-quality transgene pig rearing new variety of speed, will greatly speed up pig Germplasm enhancement and new varieties
The speed and efficiency of cultivation.
Description of the drawings
Fig. 1 is the Cas9 shear efficiencies that uciferase activity method measures different sgRNA.Wherein, sgRNA1-8 is represented respectively
The reaction system of CRISPR/Cas9-sgRNA1-8 is transfected, Control represents the positive control that kit provides.
Fig. 2 is the Cas9 shear efficiencies that Surveyor enzyme cutting methods measure different sgRNA.Wherein, Marker represents DNA molecular
Amount standard, Control1 and Control2 represent two control sgRNA that kit provides respectively, and sgRNA2,3,6 and 8 are distinguished
Represent the reaction system of transfection CRISPR/Cas9-sgRNA2,3,6 and 8.
Fig. 3 is the structure diagram of pLoxP-Sfat1.
Fig. 4 is to carry out digestion qualification result to pLoxP-Sfat1 using different restriction enzymes.Wherein, Matker
For DNA molecular amount standard.
Fig. 5 is ROSA26 sites site-directed integration Sfat1 genes schematic diagram and single cell clone qualification figure.Wherein, LA is a left side
Homology arm, PA are rabbit β-globulin polyA, and RA is right homology arm;Cre+It represents to handle by Cre adenovirus, Cre-It represents
It is handled without Cre adenovirus;M is DNA molecular amount standard, the stripe size in each electrophoretogram from top to bottom is followed successively by 4500,
3000th, 2000,1200,800,500 and 200bp.
Fig. 6 is the qualification figure that ROSA26 sites site-directed integration turns Sfat1 gene pigs.
Specific embodiment
The present invention is further described in detail With reference to embodiment, the embodiment provided is only for explaining
The bright present invention, the range being not intended to be limiting of the invention.Experimental method in following embodiments unless otherwise specified, is
Conventional method.Material, reagent, instrument etc., are commercially available unless otherwise specified used in following embodiments.
Quantitative test in following embodiment, is respectively provided with three repeated experiments, and results are averaged.
In following embodiments, unless otherwise specified, the 1st of each nucleotide sequence is the 5 ' of corresponding DNA in sequence table
Terminal nucleotide, last position are the 3 ' terminal nucleotides of corresponding DNA.
2000 transfection reagents of Lipofectamine, INVITROGEN companies, REF.11668-030, LOT.1828123;
DEME culture mediums, GIBCO companies, REF.C11995500CP, LOT.8116413.
Embodiment 1 knocks out ROSA26 genes using CRISPR/Cas9 technologies
First, the target sequence of the sgRNA of design targeting ROSA26 genes
According to the porcine ROSA 26 gene order that GenBank is announced, design in CRISPR/Cas9 technologies and target ROSA26 genes
Eight sgRNA (being denoted as sgRNA1-8) target DNA sequence, the target DNA sequence such as table 1 of eight sgRNA.
The target DNA sequence of 1 sgRNA of table
2nd, the CRISPR/Cas9-sgRNA carriers of structure targeting ROSA26 genes
It is held respectively in the positive sequence 5 ' of the target DNA of eight sgRNA of step 1 and adds in CACC joint sequences, in reverse mutual
The end of complementary series 5 ' adds in AAAC joint sequences, synthesizes the forward and reverse complementary series of the target DNA of sgRNA, and sequence is shown in Table 2.
By every sequence ddH2O is dissolved to 100 μM, takes the 15 μ l of two sequences solution of the target DNA of each sgRNA respectively
Mixing is placed in 95 DEG C of denaturation 5min, is then at the uniform velocity cooled to 16 DEG C with the speed of 0.2 DEG C/s, obtains the target DNA of eight sgRNA.
Table 2 sets up the oligonucleotide sequence of each sgRNA target DNAs of CRISPR/Cas9-sgRNA carriers
With the BsmB I digestion CRISPR/Cas9 carriers of NEB companies (hundred Olympic Competition figure Genetic Biotechnologies Co., Ltds
Carrier in UCA CRISPR/Cas9 rapid builds and activity detection kit) (digestion system is 30 μ l, wherein containing CRISPR/
2 μ g, BsmB I restriction endonucleases of Cas9 carriers, 2 μ l, 1 × NEB Buffer 3.1), 55 DEG C of incubation 2h use 1% after incubation
Ago-Gel detects digestion as a result, recycling carrier framework large fragment using DNA gel QIAquick Gel Extraction Kit, and NanoDrop measures it
Target DNA of the carrier framework large fragment respectively with each sgRNA is connect using T4DNA ligases in 20 μ g/ μ l by concentration, will
To the CRISPR/Cas9-sgRNA carriers that correctly recombinate of sequence be respectively designated as CRISPR/Cas9-sgRNA1, CRISPR/
Cas9-sgRNA2、CRISPR/Cas9-sgRNA3、CRISPR/Cas9-sgRNA4、CRISPR/Cas9-sgRNA5、CRISPR/
Cas9-sgRNA6, CRISPR/Cas9-sgRNA7 and CRISPR/Cas9-sgRNA8, this eight recombinant vectors contain respectively
The target DNA of sgRNA1-8, difference can express the sgRNA and Cas9 for targeting this eight target DNAs.
3rd, the preparation of porcine fetus fibroblasts
The selection gestation sow of 35 days, laparotomy ventrotomy take out embryo, are put into containing being washed 3 times in dual anti-D-PBS, are washed till nothing
Color.By in the embryo transfer washed to another plate, head, four limbs and tail are cut with sterile scissors, removes internal organ, continues to use D-
PBS buffer solution is washed for several times, is washed till colourless, is partially placed into remaining in the plate of 100mm, is then cut embryo with scissors
2~3mm fritters are cut into, fragment is transferred in 50ml centrifuge tubes.Add in the 0.25% of half centrifugation pipe volume
Trypsin-0.04%EDTA digestive juices, room temperature digest 15~20min or so, centre piping and druming 5 times.Add in isometric terminate liquid
The DMEM culture solutions of 10% fetal calf serum, and gently blow and beat.800rpm/min centrifuges 5min, abandons supernatant, then adds in 5ml's
DMEM culture solutions containing 20% fetal calf serum gently blow and beat suspension cell again, carry out cell count.With 2 × 105A cell/
The concentration of ml is inoculated in T25 Tissue Culture Flasks, and a full nutrient solution is replaced per 48h, will when cell growth to 80% is converged
Cell cryopreservation or secondary culture are to get to porcine fetus fibroblasts.
4th, uciferase activity method measures the shear efficiency of the Cas9 of different sgRNA
Recovery porcine fetus fibroblasts, using the DMEM medium cultures containing 10%FBS, next day treats that cell reaches
After 90% degree of converging, culture supernatant is abandoned, PBS cleaning cells are primary, extract cell genomic dna afterwards, use primer pair 1
The porcine ROSA 26 base of (CCTGAAGGACGAGACTAGCTCTAC and TCTGACCGTAAGGATGCAAGTGAG) amplification sgRNA targetings
It is sequenced because of segment, and to obtained PCR product, the Rosa26 gene orders that gained sequencing sequence and Genbank are announced
It compares, the target DNA sequence for detecting sgRNA whether there is mutation in the porcine fetus fibroblasts, as a result shows the pig fetus into fibre
The target DNA of sgRNA1-8 in cell is tieed up without mutation.
293T cells (ATCC) (cell culture medium used is the DEME culture mediums containing 10%FBS) are passed on to 96 orifice plates
(10000 cells/well), secondary daily lipofection transfect above-mentioned 8 CRISPR/Cas9-sgRNA carriers and precut
PUCA (LUC)-ROSA26-1 carriers (the UCA CRISPR/Cas9 rapid builds of hundred Olympic Competition figure Genetic Biotechnologies Co., Ltds
And carrier in activity detection kit), wherein contain 2000 transfection reagents of Lipofectamine, 2 μ l in each rotaring redyeing system,
0.8 μ g of CRISPR/Cas9-sgRNA carriers (a kind of CRISPR/Cas9-sgRNA carriers in each rotaring redyeing system), precut
0.2 μ g of pUCA (LUC)-ROSA26-1 carriers.Fresh culture is replaced after transfection 6h, continues culture for 24 hours, is drawn in 50 μ l cultures
Clearly in 96 orifice plate of White-opalescent, according to the Renilla Luciferase Assay operational manuals configuration of Promega companies
LUC reaction solutions (the Renilla of 100X Renilla Luciferase the Assay Substrate and 1ml of 10 μ l
Luciferase Assay Buffer are mixed to get), 50 μ l of LUC reaction solutions are added in every hole, are examined immediately using 96 hole light-emitting appearances
Luciferase signals are surveyed, calculate average value.And compared with Control groups, the activity of various sgRNA is analyzed.Wherein,
Control groups are the positive control that kit provides.
The results show that each group CRISPR/Cas9-sgRNA's is respectively provided with preferable cleavage activity, wherein CRISPR/Cas9-
The shear efficiency of sgRNA1,2,3,4,6 and 8 is more notable (Fig. 1).
5th, target site amplification PCR sequencing PCR measures the activity of sgRNA
Porcine fetus fibroblasts (cell culture medium used be the DEME culture mediums containing 10%FBS) are passed on to 24 orifice plates,
Secondary daily lipofection transfects above-mentioned 8 CRISPR/Cas9-sgRNA carriers, and (wherein, each rotaring redyeing system contains
2000 transfection reagents of Lipofectamine, 2 μ l, CRISPR-Cas9-sgRNA carrier, 1 μ g, each system contain one kind
CRISPR-Cas9-sgRNA carriers), cell genomic dna is extracted in transfection after 72 hours, and utilizes primer pair 1
(CCTGAAGGACGAGACTAGCTCTAC and TCTGACCGTAAGGATGCAAGTGAG) carries out the target sequence region of each sgRNA
PCR amplification and sequencing, analyze each sgRNA target sequences catastrophe.Sequencing situation is shown in Table 3.
The cutting efficiency of each sgRNA guiding Cas9 cutting target dnas of 3 sequencing analysis of table
The results show that in the system of each sgRNA guiding Cas9 cutting target dnas, in the system containing sgRNA6,1 and 2
The editorial efficiency highest of DNA has been more than 50%, in remaining system, DNA in the system containing sgRNA7,5 and 4,8 and 3
Editorial efficiency reduces successively.
6th, Surveyor enzyme cutting methods measure the Cas9 shear efficiencies of different sgRNA
Used kit is SURVEYOR MUTATION DETECTION KIT, TRANSGENOMIC companies,
CAT.706020, LOT.130421.
Porcine fetus fibroblasts (cell culture medium used be the DEME culture mediums containing 10%FBS) are passed on to 24 orifice plates,
Secondary daily lipofection transfects above-mentioned CRISPR/Cas9-sgRNA carriers, and (wherein, each rotaring redyeing system contains
2000 transfection reagents of Lipofectamine, 2 μ l, CRISPR/Cas9-sgRNA carrier, 1 μ g, each system contain one kind
CRISPR-Cas9-sgRNA carriers), cell genomic dna is extracted in transfection after 72 hours, and utilizes primer pair 1
(CCTGAAGGACGAGACTAGCTCTAC and TCTGACCGTAAGGATGCAAGTGAG) carries out the target sequence region of each sgRNA
PCR amplification carries out Surveyor digestions, 3% gel electrophoresis analysis digestion result to each PCR product.
The results show that two electrophoretic bands in the system of transfection CRISPR/Cas9-sgRNA2 after digestion are most bright, show
Efficiency highest during sgRNA2 guiding Cas9 cutting target dnas, can utilize sgRNA2 guiding Cas9 to realize ROSA26 genes
Editor.Partial results are shown in Fig. 2.
Embodiment 2 turns Sfat1 gene pigs using the structure ROSA26 site-directed integrations of target sequence 2 of embodiment 1
First, the structure of recombinant vector
1st, the structure of pCRISPR/Cas9-ROSA-sg2 carriers
Synthesis upstream and downstream oligonucleotides 5 '-CACCGCTCCTTCTCGATTATGGGCGGG-3 ' and 5 '-
AAACCCCGCCCATAATCGAGAAGGAGC-3 ' uses ddH2O is dissolved to 100 μM, takes 15 μ of upstream and downstream complementary series solution respectively
L is mixed, and is placed in 95 DEG C of denaturation 5min, is then at the uniform velocity cooled to 16 DEG C with the speed of 0.2 DEG C/s, the target DNA for obtaining sgRNA2 is double
Chain oligonucleotides.With BsmB I digestion CRISPR/Cas9 carriers (the hundred Olympic Competition figure Genetic Biotechnologies Co., Ltds of NEB companies
UCA CRISPR/Cas9 rapid builds and activity detection kit in carrier), by obtained carrier framework and the target of sgRNA2
DNA double chain oligonucleotides is connected, and the correct recombinant vector of obtained sequence is named as pCRISPR/Cas9-ROSA-sg2 (i.e.
CRISPR/Cas9-sgRNA2 in embodiment 1), pCRISPR/Cas9-ROSA-sg2 can express target sequence in targeting embodiment 1
2 sgRNA2 and Cas9.
2nd, the structure of donor template vector (pLoxP-Sfat1)
By pEasy-Sfat1 carriers (Zhou Y, Lin Y, Wu X, Feng C, Long C, Xiong F, Wang N, Pan
D,Chen H.The high-level accumulation of n-3polyunsaturated fatty acids in
transgenic pigs harboring the n-3fatty acid desaturase gene from
Caenorhabditis briggsae.Transgenic Res.2014,23 (1):EcoR I and Sac I identifications 89-97.)
DNA fragmentation between sequence replaces with the DNA fragmentation between EcoR I and Sac I the identification sequences of pCAGGS carriers, obtains pCAGGS-
Sfat1 carriers.End is glued into Hind III and Sal the I digestions of pCAGGS-Sfat1 carriers and filling-in, obtained comprising CAG
The Sfat1 of promoter and rabbit β-globulin polyA express frame.By pLoxP-neo carriers (Zhou Y, Lin Y, Wu
X,Feng C,Long C,Xiong F,Wang N,Pan D,Chen H.The high-level accumulation of n-
3polyunsaturated fatty acids in transgenic pigs harboring the n-3fatty acid
Desaturase gene from Caenorhabditis briggsae.Transgenic Res.2014,23 (1):89-
97.) end is glued with Xho I digestions and filling-in, Sfat1 expression frames is inserted into it, the sequence of acquisition is correctly recombinated into load
Body is named as pLoxP-Sfat1-neo carriers.The ROSA26 genes of sgRNA targetings are expanded from pig genome with Q5 high-fidelities enzyme
The sequence of each 1700bp in both sides or so as homology arm, and is separately added into Not I and Hpa I sites at the both ends of left homology arm,
The both ends of right homology arm are separately added into Sal I and Kpn I sites, and left and right homology arm is inserted into pLoxp-Sfat1-neo successively carries
The correct recombinant vector of obtained sequence is named as pLoxP-Sfat1 (structure diagram is shown in Fig. 3) by the corresponding site of body, is made
For donor template vector.In pLoxP-Sfat1, the sequence such as sequence of the Sfat1 expression frames between left and right homology arm and the two
In table shown in SEQ ID NO.9.
Wherein, 1-8 of SEQ ID NO.9 are the identification sequence of Not I, and 9-998 are left homology arm sequence, the
The 998-1003 identification sequences for Hpa I, the 1400-2641 sequences for CAG promoters, 2744-3943 are
The gene order of Sfat1, the 4030-4442 sequences for rabbit β-globulin polyA, 4504-4538 are loxP's
Sequence, 4564-5070 are PGK promoter sequences, and 5081-5884 are neo gene orders, and 6375-6408 are
The sequence of loxP, 6414-6419 for Sal I identify sequence, 6420-7970 be right homology arm sequence, 7987-
7970 be the identification sequence of Not I.
Shown in the gene order coding SEQ ID NO.10 of Sfat1 shown in 2744-3943 of SEQ ID NO.9
Sfat1 protein.
It is utilized respectively different restriction enzymes and digestion identification is carried out to pLoxP-Sfat1, the results are shown in Figure 4, knot
The correct recombinant vector pLoxP-Sfat1 that fruit shows.
2nd, the screening and identification of ROSA26 sites site-directed integration Sfat1 gene single cell clones
After porcine fetus fibroblasts grow into degree of converging >=80%, cell dissociation is got off with trypsase and carries out essence
It really counts, 1 000r/min centrifugation 5min remove supernatant after centrifugation, and wash 1 time with D-PBS resuspension cells centrifuges again, as possible will
Supernatant removal is clean, is then mixed with the Lonza transfection liquids of 8 μ g carriers in advance (in the transfection liquid with 100 μ L of 37 DEG C of incubations
The molar ratio of pCRISPR/Cas9-ROSA-sg2 and pLoxP-Sfat1 is 1:3) it is resuspended 1 × 106A cell, after abundant mixing,
It is transferred in electric shock cup, using NucleofectorTMConsideration convey instrument shocks by electricity, and electric shock program is T016, after electric shock terminates, by cell
It is seeded in 60mm Tissue Culture Dish, is cultivated 48 hours, gone to containing 400 μ g/ml with the DMEM containing 20% fetal calf serum
Cultivated 48 hours in the DMEM of G418 and 20% fetal calf serum, then shift to containing 400 μ g/ml G418 and 2 μM of Ganciclovir and
Culture to cell clone point occurs in the DMEM of 20% fetal calf serum.
Clone's point is marked with marking pen, and after D-PBS is washed 1 time, stainless steel clone's ring of sterilizing is positioned over clone's point
On, it adds in 1 drop trypsin digestion 3 minutes, full culture medium is added in after the completion of digestion and terminates digestion, the liquid in ring will be cloned
(containing postdigestive cell) is sucked out, and is transferred to 48 porocyte culture plates and is cultivated, and cell takes half for identifying after covering with, remain
Remaining cell cryopreservation.
Cell genomic dna is extracted, carries out PCR detections.Utilize (5 ' the GCATATCGTTTGTTACGCTGGAAG of primer pair 2
3 ' and 5 ' GGAAAGTCCCATAAGGTCATGTAC 3 ') identify whether 5 ' ends occur homologous recombination, correct homologous recombination can expand
To the DNA fragmentation that size is 1381bp;Utilize (5 ' the CAGCCTCTGTTCCACATACACTTC 3 ' and 5 ' of primer pair 3
AGCCATACTTCCAAGGCTCAACAG 3 ') identify whether 3 ' ends occur homologous recombination, correct homologous recombination can be expanded to size
DNA fragmentation for 1719bp;Utilize (5 ' the GTGCTGGTTATTGTGCTGTCTCATC 3 ' and 5 ' of primer pair 4
GCGTGGTGAAGTTTGTGACTCTTTTG3 ') identify whether Sfat1 genes are integrated into cellular genome, correct homologous recombination
It can DNA fragmentation of the amplification to size for 530bp.
Choose the positive colony cell that correct homologous recombination occurs, thaw into 48 orifice plates, it is normal to cultivate, treat cell grow to
When converging rate up to 80%, handled 48 hours with Cre adenovirus.Pancreatin digestion centrifugation, collects cell, a part of cell extraction cell
Genomic DNA, remaining cell add in micromanipulation liquid, and 1h is placed at room temperature for after resuspension and then goes to 4 DEG C spare (4 DEG C of storages is not
Preferably more than 2h).Then (5 ' the AGCTGTCCCTCTTCTCTTATGGAG 3 ' and 5 ' of primer pair 5 are utilized
AGCCATACTTCCAAGGCTCAACAG 3 ') and (5 ' CAGCCTCTGTTCCACATACACTTC3 ' and 5 ' of primer pair 6
AGCCATACTTCCAAGGCTCAACAG 3 ') whether PCR identification Neo genes be deleted, and Neo genes are not deleted primer pair 5 energy
Amplification obtains the DNA fragmentation that size is 1723bp, and primer pair 6, which can expand, obtains the DNA fragmentation that size is 3653bp, Neo genes
After deletion, primer pair 5 cannot be expanded to DNA fragmentation, and primer pair 6, which can expand, obtains the DNA fragmentation that size is 1693bp.Neo bases
Because of deleted cell as nuclear donor cell for nuclear transfer.Fig. 5.
3rd, ROSA26 gene locis turn structure and the identification of Sfat-1 gene pigs
With the syringe with 12# syringe needles, draw and physically well develop on pig (kind of a pig farm is stabilized in Beijing) ovary, be of moderate size (3
~6mm) ovarian follicle in liquid, inject 50mL centrifuge tubes in.Supernatant is abandoned after 37 DEG C of natural sedimentations, egg liquid is washed twice.It is stereoscopic
Picking cytoplasm is fine and close under microscope, ovarian cumulus wraps up 3 layers or more of egg mother cell.After cleaning 3 times with DMEM, it is transferred in 38 DEG C of trainings
(IVM1 culture solutions are the pFF, 10IU/mL into NSCU23 culture solutions by 10% to the IVM1 culture solutions of incubation 4h in foster case
The culture solution that the hCG concentration addition respective substance of PMSG, 10ng/mL EGF and 10IU/mL obtain, wherein abundant mixing, NCSU-
The formula of 23 culture solutions is:3.178g NaCl, 1.053g NaHCO are sequentially added in 300mL Milli-Q ultra-pure waters3,
0.178g KC1,0.081g KH2PO4, 0.147g MgSO4·7H2O, 0.125g CaCl2·2H2O, 0.500g D-
Glucose, 0.073g Glutamine, 0.438g Taurine, 0.273g Hypotaurine, 0.025g streptomysin,
0.033g penicillin powder between pH value is adjusted to 7.2~7.4, is finally settled to 500mL, oozing after constant volume with ultra-pure water
Pressure is 295~310mOsm thoroughly.After carrying out aseptic filtration with 0.22 μm of filter of Millipore companies SVGP01050 types, it is stored in 4
DEG C) in, after the maturation in vitro for carrying out 20h, egg mother cell is transferred to ripe liquid IVM2 (the ripe liquid IVM2 of no PMSG and hCG
Add the obtained culture solution of respective substance for pFF the and 10ng/mL EGF into NSCU23 culture solutions by 10%) in continue to train
It supports, carries out maturation in vitro.By maturation in vitro 40 hours or so accumulative, egg mother cell is gone to saturating containing a concentration of 1mg/ml
In the culture dish of the DMEM of bright matter acid enzyme, with the pipettor of 200 μ L under the microscope with piping and druming egg mother cell, treat that cumulus cell is complete
After coming off entirely, solid glass needle is used under Stereo microscope, by egg membrane form is complete, perivitelline size is suitable and has first polar body
The mature oocyte of discharge is put into spare in micromanipulation liquid.
Ripe egg mother cell is sucked with holding ovum needle under the microscope, then egg mother cell is stirred with injection needle, by ovum
Ripe first polar body is adjusted to the position at 1 o'clock of clock on mother cell;First polar body is drawn in first polar body with injection needle
The cytoplasm of 10%~20% adjacent egg mother cell of side removes ovocyte karyon;20 μm or so of diameter is selected, circle
The nuclear donor cell that shape, smooth step two obtain, is put into perivitelline, and oolemma is pressed with injection needle, make donorcells with by
The after birth contact of body ovum is closely to get to reconstructed eggs;It is (aobvious containing BSA that reconstructed eggs are added to the micromanipulation liquid containing BSA
The preparation method of microoperation liquid is as follows:0.770g NaCl, 0.0356g NaHCO3, 0.0296g MgSO4-7H2O, 0.0162g
KCl, 0.0296g KH2PO4, 0.0146g L-Glutamines, 0.1g glucose is dissolved in 60 milliliters of ultra-pure waters, abundant mixing
After dissolving, 0.238g HEPES, 0.150g taurines, 0.0065g penicillin, 0.4g bovine serum albumin(BSA)s, 0.005g sulphur are added
Adjustment pH divides in 7.2-7.4 ranges, constant volume in 100 milliliters of volumetric flasks, 0.22 μm of filter degerming after sour streptomysin, fully dissolving
Dress, be placed in 4 DEG C of preservation) in recovery 5 minutes;Then with fusion/activation liquid, (solvent of fusion/activation liquid is water, solute and its dense
Degree is respectively 0.1mmol/L MgCl2, 0.28mol/L mannitol, 0.5mmol/L HEPES, 0.1mmol/L CaCl2And
0.01% (mass percent concentration) PVA) reconstruct egg white is washed three times, then reconstructed eggs are transferred to fusion/activation liquid in batches
In, it washs 3 times, each a small amount of being put into has been paved in the 1mm integration slots of fusion liquid, will be thin in reconstructed eggs with solid glass needle
Born of the same parents are vertical with integration slot, then apply the electric pulse induced fusion of one 100 μ s, 140V with BLS cell fusion apparatus, adopt later
The chemical Assisted Activations of 4h or so are carried out with the CHX of 7.5 μ g/ml, obtain replacing with the core of pig egg cell the nuclear donor of step 2
The reconstruct cell of the core of cell.
The reconstruct cell of acquisition is cultivated in vitro, selected after 12h Successful development to 1-2 cell stages and form it is good
Good reconstructed embryo carries out embryo transfer.The receptor of embryo transfer for the large white sow of the puberty of spontaneous estrus, (stabilize kind by Beijing
Pig farm).The method of embryo transfer is to be pulled out the ovary of receptor sow by modus operandi, checks the heat condition of receptor sow,
It is preferable with follicular development, and the sow that will be ovulated is transplanted for receptor.Fallopian tubal is gently pulled out, embryo is injected into defeated ovum
The deep of pipe, every receptor sow transplant 200 pieces or so of reconstructed embryo.6 receptor sows, embryo transfer 30 days are transplanted altogether
Afterwards, using ultrasonic wave gestation detector detection receptor pig pregnancy situation, confirm receptor pig successful pregnancies.
Receptor sow is given a birth transgene clone pig by the way of spontaneous labor.Be born it is latter week within sampling birth piggy
Ear tissue carry out transgene pig PCR identification.Whether homologous recombination occurs using 5 ' end of the identification of primer pair 2;Utilize primer pair 3
Whether 3 ' end of identification occurs homologous recombination;Identify whether Sfat1 genes are successfully integrated into genome using primer pair 4.It utilizes
The porcine fetus fibroblasts genomic DNA of untransfected utilizes positive porcine fetus fibroblasts genome as negative control
DNA is as positive control.
The qualification result of negative pig and positive pig is as shown in Figure 6.The result shows that it is successfully obtained using the method for the present invention
ROSA26 gene knock-out pigs.
<110>Military medical research institute of PLA Academy of Military Sciences
<120>Prepare ROSA26 gene mutations and the method rich in unrighted acid animal
<160> 10
<170> PatentIn version 3.5
<210> 1
<211> 19
<212> DNA
<213>Artificial sequence
<220>
<223>
<400> 1
ggaggcgatg acgagatcg 19
<210> 2
<211> 20
<212> DNA
<213>Artificial sequence
<220>
<223>
<400> 2
gctccttctc gattatgggc 20
<210> 3
<211> 19
<212> DNA
<213>Artificial sequence
<220>
<223>
<400> 3
ggcgatgacg agatcgcgg 19
<210> 4
<211> 19
<212> DNA
<213>Artificial sequence
<220>
<223>
<400> 4
gatgacgaga tcgcggggg 19
<210> 5
<211> 20
<212> DNA
<213>Artificial sequence
<220>
<223>
<400> 5
gaggcgatga cgagatcgcg 20
<210> 6
<211> 19
<212> DNA
<213>Artificial sequence
<220>
<223>
<400> 6
gggattgagc aggtgtacg 19
<210> 7
<211> 20
<212> DNA
<213>Artificial sequence
<220>
<223>
<400> 7
gaaggagcaa actgacatgg 20
<210> 8
<211> 19
<212> DNA
<213>Artificial sequence
<220>
<223>
<400> 8
gctccttctc gattatggg 19
<210> 9
<211> 7972
<212> DNA
<213>Artificial sequence
<220>
<223>
<400> 9
gcggccgcga ggcaggcggg agtgcggccc gccctgcggc aaccggaggg ggagggagaa 60
gggagcggaa aagcctggaa tacggacgga gccattgctc ccgcagaggg aggagcgctt 120
cctgctcttc tcttgtcact gattggccgc ttctcctccc gccgtgtgtg aaaacacaaa 180
tggcgtgttt tggttggagt aaagctcctg tcagttacag cctcgggagt gcgcagcctc 240
ccaggaactc tcgcattgcc ccctgggtgg gtaggtaggt ggggtggaga gagctgcaca 300
ggagggcgct gtcggcctcc tgcgggggga ggggagggtc agtgaaagtg gctcccgcgc 360
gggcgtcctg ccaccctccc ctccggggga gtcggtttac ccgccgcctg ctcggctttg 420
gtatctgatt ggctgctgaa gtcctgggaa cggccccttg ttattggctt gggtcccaaa 480
tgagcgaaac cactacgcga gtcggcaggg aggcggtctt tggtacggcc ctccccgagg 540
ccagcgccgc agtgtctggc ccctcgcccc tgcgcaacgt ggcaggaagc gcgcgcagga 600
ggcgggggcg ggctgccggg ccgaggcttc tgggtggtgg tgactgcggc tccgccctgg 660
gcgtccgccg cctgaaggac gagactagct ctacctgctc tcggacccgt gggggtgggg 720
ggtggaggaa ggagtggggg gtcggtcctg ctggcttgtg ggtgggaggc gcatgttctc 780
caaaaacccg cgcgagctgc aatcctgagg gagctgcagt ggaggaggcg gagagaaggc 840
cgcacccttc tccgcagggg gaggggagtg ccgcaatacc tttatgggag ttctctgctg 900
cctccttttc ctaaggaccg ccctgggcct agaaaaatcc ctccctcccc cgcgatctcg 960
tcatcgcctc catgtcagtt tgctccttct cgattatgtt aacctactcg atcgacattg 1020
attattgact agttattaat agtaatcaat tacggggtca ttagttcata gcccatatat 1080
ggagttccgc gttacataac ttacggtaaa tggcccgcct ggctgaccgc ccaacgaccc 1140
ccgcccattg acgtcaataa tgacgtatgt tcccatagta acgccaatag ggactttcca 1200
ttgacgtcaa tgggtggagt atttacggta aactgcccac ttggcagtac atcaagtgta 1260
tcatatgcca agtacgcccc ctattgacgt caatgacggt aaatggcccg cctggcatta 1320
tgcccagtac atgaccttat gggactttcc tacttggcag tacatctacg tattagtcat 1380
cgctattacc atggtcgagg tgagccccac gttctgcttc actctcccca tctccccccc 1440
ctccccaccc ccaattttgt atttatttat tttttaatta ttttgtgcag cgatgggggc 1500
gggggggggg ggggggcgcg cgccaggcgg ggcggggcgg ggcgaggggc ggggcggggc 1560
gaggcggaga ggtgcggcgg cagccaatca gagcggcgcg ctccgaaagt ttccttttat 1620
ggcgaggcgg cggcggcggc ggccctataa aaagcgaagc gcgcggcggg cgggagtcgc 1680
tgcgcgctgc cttcgccccg tgccccgctc cgccgccgcc tcgcgccgcc cgccccggct 1740
ctgactgacc gcgttactcc cacaggtgag cgggcgggac ggcccttctc ctccgggctg 1800
taattagcgc ttggtttaat gacggcttgt ttcttttctg tggctgcgtg aaagccttga 1860
ggggctccgg gagggccctt tgtgcggggg gagcggctcg gggggtgcgt gcgtgtgtgt 1920
gtgcgtgggg agcgccgcgt gcggctccgc gctgcccggc ggctgtgagc gctgcgggcg 1980
cggcgcgggg ctttgtgcgc tccgcagtgt gcgcgagggg agcgcggccg ggggcggtgc 2040
cccgcggtgc ggggggggct gcgaggggaa caaaggctgc gtgcggggtg tgtgcgtggg 2100
ggggtgagca gggggtgtgg gcgcgtcggt cgggctgcaa ccccccctgc acccccctcc 2160
ccgagttgct gagcacggcc cggcttcggg tgcggggctc cgtacggggc gtggcgcggg 2220
gctcgccgtg ccgggcgggg ggtggcggca ggtgggggtg ccgggcgggg cggggccgcc 2280
tcgggccggg gagggctcgg gggaggggcg cggcggcccc cggagcgccg gcggctgtcg 2340
aggcgcggcg agccgcagcc attgcctttt atggtaatcg tgcgagaggg cgcagggact 2400
tcctttgtcc caaatctgtg cggagccgaa atctgggagg cgccgccgca ccccctctag 2460
cgggcgcggg gcgaagcggt gcggcgccgg caggaaggaa atgggcgggg agggccttcg 2520
tgcgtcgccg cgccgccgtc cccttctccc tctccagcct cggggctgtc cgcgggggga 2580
cggctgcctt cgggggggac ggggcagggc ggggttcggc ttctggcgtg tgaccggcgg 2640
ctctagagcc tctgctaacc atgttcatgc cttcttcttt ttcctacagc tcctgggcaa 2700
cgtgctggtt attgtgctgt ctcatcattt tggcaaagaa ttcatggtcg ctcattcctc 2760
agacgggtta tccgccacgg ctccggtcac cggcggagat gttctggttg atgctcgcgt 2820
ttctattgaa gagaagccac cacgctcctt ggattcaact caacagtcta ctgaggagga 2880
gcgcgttcaa ttgccaactg tggatgcatt ccgtcgtgcc attccacccc attgcttcga 2940
acgcgatctc accagatctc tcagatattt ggtgcaagac tttgcggccc ttgcttttct 3000
ttactttgct cttcctgtct tcgaatactt tggacttgtc ggttatctgg catggaacgt 3060
attgatggga gtcttcggat tcgctttgtt tgttgtcgga cacgattgtc ttcatggatc 3120
attctcagat aatcaagttt tgaacgatat tattggacac atcgcattct ctcctctttt 3180
ctctccctat ttcccatggc aaaagagtca caaacttcac cacgctttca ccaaccatat 3240
tgacaaagat cacggacacg tttggattca agacaaagac tatgaaaaga tgccaacatg 3300
gaagaagctg ttcaatccaa tgccgttctc gggatggctc aaatggttcc ccgtttacac 3360
actgttcgga ttctgcgatg gatctcattt ctggccatac tcttctcttt tcgtccgtga 3420
ttctgagcgt gttcaatgcg tgatttctgc cacttgctgt gtcgcttgtg cctatgttgc 3480
tctcgcgatt gctggatcct attcaaactg gttctggtac tactgggttc cactttcctt 3540
ctttggatgc atgctcgtta ttgtcaccta tcttcaacac gctgatgaag ttgctgaggt 3600
ttacgaagct gatgagtgga gtttcgtgcg tggacaaacc cagactatcg atcgtttcta 3660
tggatttgga ttggatgaga ccatgcatca catcactgac ggacacgttg cccatcattt 3720
cttcaataag attccacatt accatctgat cgaagctact gaaggtgtga agaaggtttt 3780
ggagccactg ttcgagactc agtacggata caagtaccaa gtaaattacg acttcttcgt 3840
ccgcttccta tggttcaaca tcaagctcga ctatcttgtc cataagacta aaggaatcct 3900
tcaattccga acaactcttg aggagaaggc aaaagccaag taagagctca attcactcct 3960
caggtgcagg ctgcctatca gaaggtggtg gctggtgtgg ccaatgccct ggctcacaaa 4020
taccactgag atctttttcc ctctgccaaa aattatgggg acatcatgaa gccccttgag 4080
catctgactt ctggctaata aaggaaattt attttcattg caatagtgtg ttggaatttt 4140
ttgtgtctct cactcggaag gacatatggg agggcaaatc atttaaaaca tcagaatgag 4200
tatttggttt agagtttggc aacatatgcc catatgctgg ctgccatgaa caaaggttgg 4260
ctataaagag gtcatcagta tatgaaacag ccccctgctg tccattcctt attccataga 4320
aaagccttga cttgaggtta gatttttttt atattttgtt ttgtgttatt tttttcttta 4380
acatccctaa aattttcctt acatgtttta ctagccagat ttttcctcct ctcctgacta 4440
ctcccagtca tagctgtccc tcttctctta tggagatccc tcgacctgca gcccaagctt 4500
cgagataact tcgtataatg tatgctatac gaagttatgt cgagggcccc tgcaggtcaa 4560
ttctaccggg taggggaggc gcttttccca aggcagtctg gagcatgcgc tttagcagcc 4620
ccgctgggca cttggcgcta cacaagtggc ctctggcctc gcacacattc cacatccacc 4680
ggtaggcgcc aaccggctcc gttctttggt ggccccttcg cgccaccttc tactcctccc 4740
ctagtcagga agttcccccc cgccccgcag ctcgcgtcgt gcaggacgtg acaaatggaa 4800
gtagcacgtc tcactagtct cgtgcagatg gacagcaccg ctgagcaatg gaagcgggta 4860
ggcctttggg gcagcggcca atagcagctt tgctccttcg ctttctgggc tcagaggctg 4920
ggaaggggtg ggtccggggg cgggctcagg ggcgggctca ggggcggggc gggcgcccga 4980
aggtcctccg gaggcccggc attctgcacg cttcaaaagc gcacgtctgc cgcgctgttc 5040
tcctcttcct catctccggg cctttcgacc tgcagccaat atgggatcgg ccattgaaca 5100
agatggattg cacgcaggtt ctccggccgc ttgggtggag aggctattcg gctatgactg 5160
ggcacaacag acaatcggct gctctgatgc cgccgtgttc cggctgtcag cgcaggggcg 5220
cccggttctt tttgtcaaga ccgacctgtc cggtgccctg aatgaactgc aggacgaggc 5280
agcgcggcta tcgtggctgg ccacgacggg cgttccttgc gcagctgtgc tcgacgttgt 5340
cactgaagcg ggaagggact ggctgctatt gggcgaagtg ccggggcagg atctcctgtc 5400
atctcacctt gctcctgccg agaaagtatc catcatggct gatgcaatgc ggcggctgca 5460
tacgcttgat ccggctacct gcccattcga ccaccaagcg aaacatcgca tcgagcgagc 5520
acgtactcgg atggaagccg gtcttgtcga tcaggatgat ctggacgaag agcatcaggg 5580
gctcgcgcca gccgaactgt tcgccaggct caaggcgcgc atgcccgacg gcgatgatct 5640
cgtcgtgacc catggcgatg cctgcttgcc gaatatcatg gtggaaaatg gccgcttttc 5700
tggattcatc gactgtggcc ggctgggtgt ggcggaccgc tatcaggaca tagcgttggc 5760
tacccgtgat attgctgaag agcttggcgg cgaatgggct gaccgcttcc tcgtgcttta 5820
cggtatcgcc gctcccgatt cgcagcgcat cgccttctat cgccttcttg acgagttctt 5880
ctgaggggat cgatccgctg taagtctgca gaaattgatg atctattaaa caataaagat 5940
gtccactaaa atggaagttt ttcctgtcat actttgttaa gaagggtgag aacagagtac 6000
ctacattttg aatggaagga ttggagctac gggggtgggg gtggggtggg attagataaa 6060
tgcctgctct ttactgaagg ctctttacta ttgctttatg ataatgtttc atagttggat 6120
atcataattt aaacaagcaa aaccaaatta agggccagct cattcctccc actcatgatc 6180
tatagatcta tagatctctc gtgggatcat tgtttttctc ttgattccca ctttgtggtt 6240
ctaagtactg tggtttccaa atgtgtcagt ttcatagcct gaagaacgag atcagcagcc 6300
tctgttccac atacacttca ttctcagtat tgttttgcca agttctaatt ccatcagaag 6360
ctgactctag caatataact tcgtataatg tatgctatac gaagttatct agagtcgacg 6420
ggcgggattc ttttgccctg gcttaacctg attcttgggc gttgtcctgc aggggattga 6480
gcaggtgtac gaggacgagc ccaatttctc tatattccca cagtcttgag tttgtgtcac 6540
aaaataatta tagtggggtg gagatgggaa atgagtccag gcaacaccta agcctgattt 6600
tatgcattga gactgcgtgt tattactaaa gatctttgtg tcgcaatttc ctgatgaagg 6660
gagataggtt aaaaagcacg gatctactga gttttacagt catcccattt gtagactttt 6720
gctacaccac caaagtatag catctgagat taaatattaa tctccaaacc ttaggccccc 6780
tcacttgcat ccttacggtc agataactct cactcatact ttaagcccat tttgtttgtt 6840
gtacttgctc atccagtccc agacatagca ttggctttct cctcacctgt tttaggtagc 6900
cagcaagtca tgaaatcaga taagttccac caccaattaa cactacccat cttgagcata 6960
ggcccaacag tgcatttatt cctcatttac tgatgttcgt gaatatttac cttgattttc 7020
atttttttct ttttcttaag ctgggatttt actcctgacc ctattcacag tcagatgatc 7080
ttgactacca ctgcgattgg acctgaggtt cagcaatact cccctttatg tcttttgaat 7140
acttttcaat aaatctgttt gtattttcat tagttagtaa ctgagctcag ttgccgtaat 7200
gctaatagct tccaaactag tgtctctgtc tccagtatct gataaatctt aggtgttgct 7260
gggacagttg tcctaaaatt aagataaagc atgaaaataa ctgacacaac tccattactg 7320
gctcctaact acttaaacaa tgcattctat cttcacaaat gtgaaaaagg agttccctca 7380
gtggactaac cttatctttt ctcaacacct ttttctttgc acaattttcc acacatgcct 7440
acaaaaagta cttttctgct caagtcacac tgagttgatt gctatttacc aaaatcaaag 7500
taacattatc agatctctgt agggtggttc cctctggaat gctaccctcc atagtcctta 7560
cccttcaagt aaagagcatg aagactgaaa tatctcctct gtgatctgtc atcctttaag 7620
ccagaatccc ccataaaaaa gttagtattg ctttctcctg atcccatagc aggttgaatc 7680
atagcactta tcaggttgtt gtcattgctt gcttaaattc tcctaactat ttggagcttc 7740
ttgagggcac aggttcttgt tgagtcttgt acctaagcac ctagtatagt ccttgatgtc 7800
tagccaaccc taaataaaat gcagtgagtg acatgtagat gtctttataa ggtttgatag 7860
gttggtctct caaatagttc ttttgtatgt ttggtagtgc tctagattag cactggccag 7920
tataactctg atgatggaaa tgttctatag ctatgctgtc taatatggta cc 7972
<210> 10
<211> 399
<212> PRT
<213>Artificial sequence
<220>
<223>
<400> 10
Met Val Ala His Ser Ser Asp Gly Leu Ser Ala Thr Ala Pro Val Thr
1 5 10 15
Gly Gly Asp Val Leu Val Asp Ala Arg Val Ser Ile Glu Glu Lys Pro
20 25 30
Pro Arg Ser Leu Asp Ser Thr Gln Gln Ser Thr Glu Glu Glu Arg Val
35 40 45
Gln Leu Pro Thr Val Asp Ala Phe Arg Arg Ala Ile Pro Pro His Cys
50 55 60
Phe Glu Arg Asp Leu Thr Arg Ser Leu Arg Tyr Leu Val Gln Asp Phe
65 70 75 80
Ala Ala Leu Ala Phe Leu Tyr Phe Ala Leu Pro Val Phe Glu Tyr Phe
85 90 95
Gly Leu Val Gly Tyr Leu Ala Trp Asn Val Leu Met Gly Val Phe Gly
100 105 110
Phe Ala Leu Phe Val Val Gly His Asp Cys Leu His Gly Ser Phe Ser
115 120 125
Asp Asn Gln Val Leu Asn Asp Ile Ile Gly His Ile Ala Phe Ser Pro
130 135 140
Leu Phe Ser Pro Tyr Phe Pro Trp Gln Lys Ser His Lys Leu His His
145 150 155 160
Ala Phe Thr Asn His Ile Asp Lys Asp His Gly His Val Trp Ile Gln
165 170 175
Asp Lys Asp Tyr Glu Lys Met Pro Thr Trp Lys Lys Leu Phe Asn Pro
180 185 190
Met Pro Phe Ser Gly Trp Leu Lys Trp Phe Pro Val Tyr Thr Leu Phe
195 200 205
Gly Phe Cys Asp Gly Ser His Phe Trp Pro Tyr Ser Ser Leu Phe Val
210 215 220
Arg Asp Ser Glu Arg Val Gln Cys Val Ile Ser Ala Thr Cys Cys Val
225 230 235 240
Ala Cys Ala Tyr Val Ala Leu Ala Ile Ala Gly Ser Tyr Ser Asn Trp
245 250 255
Phe Trp Tyr Tyr Trp Val Pro Leu Ser Phe Phe Gly Cys Met Leu Val
260 265 270
Ile Val Thr Tyr Leu Gln His Ala Asp Glu Val Ala Glu Val Tyr Glu
275 280 285
Ala Asp Glu Trp Ser Phe Val Arg Gly Gln Thr Gln Thr Ile Asp Arg
290 295 300
Phe Tyr Gly Phe Gly Leu Asp Glu Thr Met His His Ile Thr Asp Gly
305 310 315 320
His Val Ala His His Phe Phe Asn Lys Ile Pro His Tyr His Leu Ile
325 330 335
Glu Ala Thr Glu Gly Val Lys Lys Val Leu Glu Pro Leu Phe Glu Thr
340 345 350
Gln Tyr Gly Tyr Lys Tyr Gln Val Asn Tyr Asp Phe Phe Val Arg Phe
355 360 365
Leu Trp Phe Asn Ile Lys Leu Asp Tyr Leu Val His Lys Thr Lys Gly
370 375 380
Ile Leu Gln Phe Arg Thr Thr Leu Glu Glu Lys Ala Lys Ala Lys
385 390 395
Claims (10)
1. it is mutated the method for ROSA26 genes, it is characterised in that:The method is carried out using CRISPR/Cas9 systems, described
CRISPR/Cas9 systems include the sgRNA of targeting ROSA26 genes, and the target sequence of the sgRNA is following A1), A2) or A3):
A1) in sequence table sequence 2 nucleotide sequence;
A2 the DNA sequence dna) and A1) limited have 75% or more than 75% homogeneity as A1) derived from DNA sequence dna;
A3) under strict conditions with A1) limit DNA sequence dna hybridize as A1) derived from DNA sequence dna.
2. according to the method described in claim 1, it is characterized in that:Described in being imported into recipient cell
SgRNA and Cas9 realizes the mutation of ROSA26 genes.
3. according to the method described in claim 2, it is characterized in that:It is described that the sgRNA and Cas9 is imported into recipient cell
Described in being imported by the expression vector of the expression vector of the encoding gene that will contain the sgRNA and the encoding gene containing Cas9
It is realized in recipient cell.
4. according to the method described in claim 3, it is characterized in that:The expression of the encoding gene containing the sgRNA carries
The expression vector of body and the encoding gene containing Cas9 is same carrier, which is named as carrier 1, the carrier
1 is the recombinant vector obtained by DNA fragmentations of the BsmB I into CRISPR/Cas9 carriers shown in insetion sequence 2, the carrier
1 can express sgRNA and Cas9 described in claim 1.
5. according to the method any in claim 2-4, it is characterised in that:The method is further included to the recipient cell
Middle importing donor dna realizes the mutation of ROSA26 genes, and the donor dna, which contains, is located at the target sequence in ROSA26 genes
Two DNA fragmentations of upstream and downstream.
6. according to the method described in claim 5, it is characterized in that:The donor dna also containing Sfat1 encoding genes or
The expression cassette of Sfat1 encoding genes.
Any one of 7. following 1) -6):
1) method for preparing ROSA26 Genetic Mutant Cells, including:It is prepared into using the method any in claim 1-6
To the cell of ROSA26 gene mutations;
2) method for preparing ROSA26 gene mutant animals, including:It is prepared using the method any in claim 1-6
The zooblast of ROSA26 gene mutations prepares ROSA26 gene mutations using the zooblast of the ROSA26 gene mutations and moves
Object;
3) method for preparing expression Sfat1 cells, including:ROSA26 genes are prepared using the method described in claim 6 to dash forward
The zooblast of change obtains the cell of expression Sfat1;
4) method for preparing expression Sfat1 animals, including:ROSA26 genes are prepared using the method described in claim 6 to dash forward
The zooblast of change obtains the cell of expression Sfat1;The animal of expression Sfat1 is prepared using the cell of the expression Sfat1;
5) method rich in unrighted acid cell is prepared, including:ROSA26 is prepared using the method described in claim 6
The zooblast of gene mutation obtains the cell rich in unrighted acid;
6) method rich in unrighted acid animal is prepared, including:ROSA26 is prepared using the method described in claim 6
The zooblast of gene mutation obtains the cell of expression Sfat1;It is prepared using the cell of the expression Sfat1 rich in unsaturation
The animal of aliphatic acid.
8. according to the method any in claim 1-7, it is characterised in that:The cell be following a1) a2) or a3):
A1) zooblast;
A2) mammalian cell;
A3) pig cell;
The animal is b1) or b2):
B1) mammal;
A2) pig.
9. the cell or described that the method for ROSA26 Genetic Mutant Cells obtains is prepared described in 7 or 8 the method for claim
The cell or the method for the preparation rich in unrighted acid cell that the method for preparing expression Sfat1 cells obtains obtain thin
Born of the same parents.
10. application of any the method in animal breeding in claim 1-9.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810038598.1A CN108192928A (en) | 2018-01-16 | 2018-01-16 | Prepare ROSA26 gene mutations and the method rich in unrighted acid animal |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810038598.1A CN108192928A (en) | 2018-01-16 | 2018-01-16 | Prepare ROSA26 gene mutations and the method rich in unrighted acid animal |
Publications (1)
Publication Number | Publication Date |
---|---|
CN108192928A true CN108192928A (en) | 2018-06-22 |
Family
ID=62589163
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810038598.1A Pending CN108192928A (en) | 2018-01-16 | 2018-01-16 | Prepare ROSA26 gene mutations and the method rich in unrighted acid animal |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108192928A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109112161A (en) * | 2018-08-17 | 2019-01-01 | 华中农业大学 | The method for preparing the animal of ROSA26 gene mutation and intramuscular fat raising |
CN115245144A (en) * | 2022-05-19 | 2022-10-28 | 南京启真基因工程有限公司 | Kit for preparing pig rich in omega-3fatty acid and preparation method and application thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105087620A (en) * | 2015-08-31 | 2015-11-25 | 中国农业大学 | Overexpression porcine co-stimulatory 4-1BB vector and application thereof |
CN105647968A (en) * | 2016-02-02 | 2016-06-08 | 浙江大学 | Fast CRISPR-Cas9 working efficiency testing system and application thereof |
CN106916820A (en) * | 2017-05-16 | 2017-07-04 | 吉林大学 | SgRNA and its application of porcine ROSA 26 gene can effectively be edited |
-
2018
- 2018-01-16 CN CN201810038598.1A patent/CN108192928A/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105087620A (en) * | 2015-08-31 | 2015-11-25 | 中国农业大学 | Overexpression porcine co-stimulatory 4-1BB vector and application thereof |
CN105647968A (en) * | 2016-02-02 | 2016-06-08 | 浙江大学 | Fast CRISPR-Cas9 working efficiency testing system and application thereof |
CN106916820A (en) * | 2017-05-16 | 2017-07-04 | 吉林大学 | SgRNA and its application of porcine ROSA 26 gene can effectively be edited |
Non-Patent Citations (4)
Title |
---|
GENEBANK: "登录号:NC_010455.5", 《GENEBANK》 * |
GUOLING LI ET AL.: "Small molecules enhance CRISPR/Cas9-mediated homology-directed genome editing in primary cells", 《SCIENTIFIC REPORTS》 * |
无: "世界首例ROSA26基因敲入猪模型诞生", 《中国动物检疫》 * |
程英: "ZFNs介导肝脏特异性表达外源基因hsfat-1在猪ROSA26位点整合与重构胚的制备", 《中国优秀硕士学位论文全文数据库 农业科技辑》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109112161A (en) * | 2018-08-17 | 2019-01-01 | 华中农业大学 | The method for preparing the animal of ROSA26 gene mutation and intramuscular fat raising |
CN115245144A (en) * | 2022-05-19 | 2022-10-28 | 南京启真基因工程有限公司 | Kit for preparing pig rich in omega-3fatty acid and preparation method and application thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210112790A1 (en) | Pathogen-resistant animals having modified cd163 genes | |
CN105087620B (en) | One kind is overexpressed the 1BB carriers of pig costimulation acceptor 4 and its application | |
JP2022031487A (en) | Genetically modified cells, tissues and organs for treating disease | |
US11160260B2 (en) | Methods for protecting porcine fetuses from infection with porcine reproductive and respiratory syndrome virus (PRRSV) | |
JP2022081637A (en) | Porcine reproductive and respiratory syndrome virus resistant animals | |
CN104561095A (en) | Preparation method for transgenic mice capable of producing human nerve growth factor | |
PT2152880E (en) | Compositions and methods for inhibiting endogenous immunoglobulin genes and producing transgenic human idiotype antibodies | |
CN113957069B (en) | Composition for simultaneous modification of amino acids at 736 th site and 738 th site of pAPN gene and application thereof | |
US20200236914A1 (en) | Pathogen-resistant animals having modified aminopeptidase n (anpep) genes | |
CN113957093B (en) | System for site-directed modification of pAPN gene and application thereof | |
CN111575319B (en) | Efficient CRISPR RNP and donor DNA co-location mediated gene insertion or replacement method and application thereof | |
CN114231533B (en) | Preparation method of miniature pig with human complement regulatory protein knocked in at Rosa26 site by fixed point | |
CN108018288A (en) | For being mutated system and its application of ROSA26 genes | |
CN113604504A (en) | Composition for site-directed modification of pAPN gene 16 exon and application thereof | |
CN101260398B (en) | Nerve growth factor gene positioning reconstruction animal and its preparation method and application | |
CN108192928A (en) | Prepare ROSA26 gene mutations and the method rich in unrighted acid animal | |
CN101918557A (en) | Method of genetically altering and producing allergy free cats | |
CN109112161A (en) | The method for preparing the animal of ROSA26 gene mutation and intramuscular fat raising | |
AU2001245438A1 (en) | A new vector for genetically modifying non-human animals | |
CN113604502A (en) | Gene editing system of pAPN gene 16 th exon and application thereof | |
WO2015163711A1 (en) | Talen targeting myostatin gene and method for making animal with knockout myostatin gene using same | |
US10717991B2 (en) | Transgenic pig which simultaneously expresses HO-1 gene and TNFR1-Fc gene, and comprises knocked-out GGTA1 gene, and use thereof | |
WO2019203807A1 (en) | Methods for protecting porcine fetuses from infection with virus | |
CN113234758B (en) | Method for constructing traceless engineering animal by using PiggyBac transposase system | |
KR20230092097A (en) | Transgenic cloned piglets defecting porcine GGTA1, CMAH, beta4GalNT2 and CD40 gene for xenotransplantation, and producing method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |